Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
-Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS-
NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) ('Helius' or the 'Company'), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare.
'The recent reimbursement approvals from two major commercial healthcare payers, with a third underway, mark significant milestones for Helius and the MS community,' said Dane Andreeff, Helius' President and Chief Executive Officer. 'We are actively pursuing broader in-network coverage for PoNS at list price from major commercial payers, while continuing to negotiate reimbursement on a case-by-case basis. We expect to continue our efforts in expanding patient access and ensuring consistent reimbursement as we work to align commercial payments with the rates currently offered by the VA/DoD at $26,228. At the same time, we remain firmly committed to supporting individuals with MS who rely on Medicare for PoNS treatment and believe this, along with other 3rd party payer reimbursement decisions will benefit our continued efforts to secure fair and adequate reimbursement by CMS for the PoNS system.'
The out-of-network price, which typically is 30 to 40% below in-network contracted payment rates of $18,350, was negotiated and accepted by Aetna Healthcare to fulfill the prescription of the PoNS Device for an individual with multiple sclerosis. Depending on the individual's deductible and out-of-pocket costs, this claim may not result in an immediate PoNS Device sale.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator ('PoNS') is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it's used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury ('mmTBI') and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short-term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS® or Helius Medical Technologies, visit www.heliusmedical.com.
Cautionary Disclaimer Statement
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, statements regarding commercial reimbursement of the PoNS Device and the uses and effectiveness of PoNS and PoNS Therapy.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties associated with the Company's capital requirements to achieve its business objectives, availability of funds, the Company's ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company's ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company's ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Investor Relations Contact
Philip Trip TaylorGilmartin Groupinvestorrelations@heliusmedical.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
TeraWulf Launches $400 Million Convertible Notes Offering To Fund Data Center Expansion
TeraWulf (NASDAQ:WULF), an operator of vertically integrated, predominantly zero-carbon digital infrastructure, launched a private offering of $400 million aggregate principal amount of convertible senior notes due 2031. The company may also grant initial purchasers a 13-day option to buy up to an additional $60 million of notes. TeraWulf plans to use the proceeds primarily to fund capped call transactions to reduce dilution from potential note will allocate the remaining proceeds toward expanding its data centers and supporting general corporate purposes. The notes will be senior unsecured obligations, paying semiannual interest starting March 1, 2026, and maturing September 1, 2031. Regarding pricing, TeraWulf expects to enter into capped call transactions with financial institutions to mitigate dilution from potential conversions. Separately, TeraWulf announced that Fluidstack has expanded its footprint at the Lake Mariner data center campus in Western New York. The expansion introduces CB-5, a new purpose-built data center that will add 160 MW of critical IT load when operations begin in the second half of 2026. As part of the CB-5 lease, Alphabet's (NASDAQ:GOOGL) (NASDAQ:GOOG) Google committed an additional $1.4 billion to backstop project-related debt financing and secured warrants to purchase 32.5 million TeraWulf shares. This new commitment raises Google's total backstop to $3.2 billion and expands its pro forma equity stake in TeraWulf to about 14%. The CB-5 lease mirrors the economics of Fluidstack's earlier CB-3 and CB-4 agreements, ensuring consistent terms across the Lake Mariner buildout. With CB-5, TeraWulf boosts Fluidstack's total contracted capacity to approximately 360 MW, making Lake Mariner one of the largest high-performance computing campuses in the United States. TeraWulf and Fluidstack are also discussing further expansions to meet growing AI demand. TeraWulf stock has gained close to 59% year-to-date and over 78% in the last five days upon the Google deal. TeraWulf shares extended their rally last Friday after the company cemented a landmark deal, strengthening its role in artificial intelligence infrastructure. The stock jumped more than 40% in last Thursday's midday trading and has climbed 78% since Monday's open. On Thursday, TeraWulf signed two 10-year high-performance computing (HPC) colocation agreements with Fluidstack, locking in approximately $3.7 billion in contracted revenue. Under the agreements, TeraWulf will supply more than 200 MW of power from its Lake Mariner data center in New York, with extension options that could lift the contract's total value to $8.7 billion. Google fueled momentum by backing $1.8 billion of Fluidstack's lease obligations and securing warrants for an 8% equity stake in TeraWulf. The announcement followed a stronger-than-expected quarterly report. TeraWulf reported a second-quarter loss of 5 cents per share, beating the 7-cent loss forecast. Sales reached $47.64 million, above the $46.08 million estimate. CEO Paul Prager also pointed to integrating Beowulf Electricity & Data to streamline operations and cut costs. Price Action: WULF stock is trading lower by 4.01% to $8.620 premarket at last check Monday. Photo by Gorodenkoff via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article TeraWulf Launches $400 Million Convertible Notes Offering To Fund Data Center Expansion originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Chicago Tribune
16 minutes ago
- Chicago Tribune
Wall Street is quiet in premarket trading ahead of Trump's meeting with Ukraine's Zelenskyy
Wall Street ticked modestly lower early Monday ahead of U.S. President Donald Trump's meeting later Monday with Ukrainian President Volodymyr Zelenskyy and other European leaders. Futures for the S&P 500, Dow Jones Industrial Average and Nasdaq were all 0.1% lower before the bell. Markets showed scant reaction to Trump's inconclusive summit meeting with Russian President Vladimir Putin on Friday. Investors are also watching for cues from an annual meeting in Jackson Hole, Wyoming, of top central bankers later this week. In premarket trading, Soho House jumped 16% after the global membership-based club said it was being taken private by hotel operator MCR. Executive Chairman Ron Burkle and other big shareholders will retain their equity interests and control of the business. Dayforce, a human resources software company, climbed more than 28% before the bell on media reports that it is being acquired by Chicago-based private equity firm Thoma Bravo. Bloomberg reported that Thoma Bravo was offering $9 billion, including debt, to take Dayforce private. Some of the biggest U.S. retailers will report their latest financial results throughout the week, including Home Depot, Target and Walmart. Trump's meeting with Zelenskyy will include other European leaders who were not included in the president's talks in Anchorage, Alaska, with Putin. The European allies are seeking to present a united front in safeguarding Ukraine and the continent from any widening aggression from Moscow. An annual meeting in Jackson Hole, Wyoming, of top central bankers later this week will be watched closely for hints about possible interest rate cuts from Federal Reserve chair Jerome Powell. He is due to speak Friday at the conference. 'While the official theme is labor markets, investors will scrutinize any hint of September policy direction, especially after last week's mixed inflation data,' Ipek Ozkardeskaya of Swissquote said in a commentary, adding that 'any progress on Ukraine peace talks could push global equities higher still.' Expectations have been building that the Fed will cut interest rates at its next meeting in September, though mixed reports on the U.S. economy have undercut those bets somewhat. At midday in Europe, Germany's DAX lost 0.3%, while the CAC 40 in Paris dropped 0.7%. Britain's FTSE 100 was flat. In Asia, Japan's Nikkei 225 picked up 0.8%, while the Hang Seng in Hong Kong gave up early gains, losing 0.4%. The Shanghai Composite index jumped 1%. It's trading near it's highest level in a decade. Australia's S&P/ASX 200 picked up 0.2%. The Kospi in South Korea declined 1.5% on heavy selling of semiconductor makers like Samsung Electronics, whose shares fell 2.2%. SK Hynix lost 3.3% as investors fretted over the possibility of more U.S. tariffs on computer chips.
Yahoo
31 minutes ago
- Yahoo
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
- In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-related primary osteoarthritis patients compared with placebo – a substantial, clinically meaningful and statistically significant effect in commonly used Phase III primary endpoints for knee osteoarthritis clinical trials. - Favorable safety profile – No severe adverse events; limited, typically mild to moderate, transient, and treatable side effects occurred in most patients treated with Allocetra™ - Webinar today at 8:00 a.m. Eastern Time Nes-Ziona, Israel, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the 'Company'), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis. Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, 'We are excited to share the topline three-month data from ENX-CL-05-001. We believe these results provide clear indication that Allocetra™ has the potential to become a novel, safe and effective treatment for knee osteoarthritis, a growing market with significant unmet medical need.' The Company will host a webinar today at 8:00 am Eastern Time to provide in-depth analysis of the results. To join the webinar, please click To join the webinar, please register at: It is suggested participants join the webinar at least 15 minutes prior to the scheduled start time to avoid any delays in attendance. About ENX-CL-05-001ENX-CL-05-001 is a multi-center Phase I/II clinical trial consisting of two stages. The first stage was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra™ injections to the target knee, in order to identify the dose and injection regimen for the subsequent Phase IIa stage. The Phase IIa stage is a double-blind, randomized, placebo-controlled multi-centered trial. In addition to evaluating safety, the study protocol was designed to efficiently find a strong signal in a responder population to guide future development, and includes an interim statistical evaluation, conducted by an independent third party and blinded to the Company, to assess the potential value of enrollment of up to 50 patients in addition to the original randomized sample size of 130, and its marginal impact on the p-value of the statistical estimation of the total group and specifically to identify a potential responder sub-group. The trial's key efficacy endpoints evaluate joint-pain and joint-function in comparison to placebo at three months, six months and 12 months post treatment. ABOUT KNEE OSTEOARTHRITIS Osteoarthritis is by far the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. About half of knees with ACL injuries develop osteoarthritis within 5 to 15 years. 78 million Americans are projected to have osteoarthritis by the year 2040. Symptomatic knee osteoarthritis is particularly prevalent and disabling, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes. Osteoarthritis accounts for over one million hospitalizations annually in the United States, primarily for total joint replacement. The burden of osteoarthritis is enormous, and the need for treatments that reduce pain and attendant disability for persons with osteoarthritis is critical. There are currently no medications approved by either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) that have been demonstrated to arrest, slow or reverse progression of structural damage in the joint. ABOUT ENLIVEX Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'may,' 'anticipates,' 'believes,' 'should,' 'would,' 'could,' 'intends,' 'estimates,' 'suggests,' 'target,' 'has the potential to' and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Therapeutics, INVESTOR RELATIONS CONTACT Dave Gentry, CEORedChip Companies Inc.1-407-644-4256ENLV@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
